Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis

Cherian, Sindhu; McCullouch, Vivian; Miller, Valerie; Dougherty, Katy J.; Fromm, Jonathan R.; Wood, Brent L.

doi:10.1002/cyto.b.21336

Cited by 13 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although serum tryptase levels were normal in all patients, mast cells showed coexpression of CD25 in one patient (Patient #1) assessed by FCI. Of note, besides the setting of systemic mastocytosis, CD25 can be coexpressed by activated mast cells (Cherian et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution

Wang

Thakral

et al. 2020

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: Lymphocytic variant of hypereosinophilic syndrome (L-HES) is a subtype of HES driven by cytokines produced by clonal T-cells. Due to the rarity of its occurrence and challenges in diagnosis, this subtype of HES is under recognized. Methods and Results: We report seven patients with L-HES, diagnosed from a group of 136 patients who were referred to our institution for the work-up of hypereosinophilia. The clinical presentation, symptoms and signs were heterogeneous and uncharacteristic; indistinguishable from idiopathic HES. Flow cytometry immunophenotypic analysis revealed aberrant T-cells in all patients, with a Th2 immunophenotype, CD2 + CD3−CD4 + CD5 + CD7dim+/−CD8− in six of seven (86%) cases. CD10 was partially expressed in one of seven (14%) cases, and clonal TCR gene rearrangement was detected by PCR in five of seven (71%) patients. All patients were treated with corticosteroids and two of seven (29%) patients received anti-IL5 antibody therapy. With a median follow-up time of 7.5 years (2.3-14.1 years), one (11%) patient developed peripheral T-cell lymphoma 6.1 years after the initial diagnosis of L-HES and responded well to chemotherapy. All patients were alive at the last follow-up. Conclusion: In conclusion, a combination of flow cytometry immunophenotyping and molecular analysis allows the identification of aberrant T-cells, facilitating a diagnosis of L-HES in patients with eosinophilia. A correct diagnosis is essential for the proper management of these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution

Wang

Thakral

et al. 2020

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

“…111 Like CD25 and CD2, CD30 may be occasionally expressed in a subset of normal/reactive MCs at a low level. 114 However, expression of two or more aberrant markers or strong uniform expression of at least one of the three markers is strongly associated with SM. It is important to be aware that in some cases of SM, 115 the major criterion of aggregates of ≥15 MC in the BM or tissue biopsy is not present, and the diagnosis relies on the presence of three or all four minor criteria; therefore, in this setting, documentation of MC morphology and identifying a MC-associated aberrant immunophenotype become essential.…”

Section: Histopathologymentioning

confidence: 99%

The international consensus classification of eosinophilic disorders and systemic mastocytosis

et al. 2023

View full text Add to dashboard Cite

Based on new data and increased understanding of disease molecular genetics, the international consensus classification (ICC) has made several changes in the diagnosis and classification of eosinophilic disorders and systemic mastocytosis. Myeloid/lymphoid neoplasms with eosinophilia (M/LN‐eo) and gene rearrangements have been renamed as M/LN‐eo with tyrosine kinase gene fusions (M/LN‐eo‐TK). The category has been expanded to include ETV6::ABL1 and FLT3 fusions, and to accept PCM1::JAK2 and its genetic variants as formal members. The overlaps and differences between M/LN‐eo‐TK and BCR::ABL1‐like B‐lymphoblastic leukemia (ALL)/de novo T‐ALL sharing the same genetic lesions are addressed. Besides genetics, ICC for the first time has introduced bone marrow morphologic criteria in distinguishing idiopathic hypereosinophilia/hypereosinophilic syndrome from chronic eosinophilic leukemia, not otherwise specified. The major diagnostic criteria for systemic mastocytosis (SM) in the ICC remain largely based on morphology, but several minor modifications/refinements have been made in criteria related to diagnosis, subclassification, and assessment of disease burden (B‐ and C‐findings). This review is to focus on the ICC updates related to these disease entities, illustrated through changes related to morphology, molecular genetics, clinical features, prognosis, and treatment. Two practical algorithms are provided in navigating through the diagnosis and classification systems of hypereosinophilia and SM.

show abstract

“…A definitive diagnosis of SM can be made in the presence of 1 major and 1 minor criteria or if 3 minor SM criteria are fulfilled. However, it is important to note that aberrant expression of CD2 and/or CD25 may be found on mast cells in other clinical settings such as post chemotherapy 8 and in indolent SM tryptase levels may be only slightly increased and can be normal in cases of low-level bone marrow involvement 9 – 11 . Other clinical parameters have been explored to aid diagnosis and subtype classification, increased IL6 plasma levels may be indicative of disease progression from indolent to aggressive 12 .…”

Section: Introductionmentioning

confidence: 99%

SWATH-MS identification of CXCL7, LBP, TGFβ1 and PDGFRβ as novel biomarkers in human systemic mastocytosis

Graham

McMullen

Moore

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Mastocytosis is a rare myeloproliferative disease, characterised by accumulation of neoplastic mast cells in one or several organs. It presents as cutaneous or systemic. Patients with advanced systemic mastocytosis have a median survival of 3.5 years. The aetiology of mastocytosis is poorly understood, patients present with a broad spectrum of varying clinical symptoms that lack specificity to point clearly to a definitive diagnosis. Discovery of novel blood borne biomarkers would provide a tractable method for rapid identification of mastocytosis and its sub-types. Moving towards this goal, we carried out a clinical biomarker study on blood from twenty individuals (systemic mastocytosis: n = 12, controls: n = 8), which were subjected to global proteome investigation using the novel technology SWATH-MS. This identified several putative biomarkers for systemic mastocytosis. Orthogonal validation of these putative biomarkers was achieved using ELISAs. Utilising this workflow, we identified and validated CXCL7, LBP, TGFβ1 and PDGF receptor-β as novel biomarkers for systemic mastocytosis. We demonstrate that CXCL7 correlates with neutrophil count offering a new insight into the increased prevalence of anaphylaxis in mastocytosis patients. Additionally, demonstrating the utility of SWATH-MS for the discovery of novel biomarkers in the systemic mastocytosis diagnostic sphere.

show abstract

Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis

Cited by 13 publications

References 15 publications

Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution

Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution

The international consensus classification of eosinophilic disorders and systemic mastocytosis

SWATH-MS identification of CXCL7, LBP, TGFβ1 and PDGFRβ as novel biomarkers in human systemic mastocytosis

Contact Info

Product

Resources

About